Biotech entity
All 1 tracked stories fall under one category: pharma. NGGT is most often covered alongside Aparna Thakur, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.4 across the same-window beat baseline.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. NGGT is most often covered alongside Aparna Thakur, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.4 across the same-window beat baseline. The average consequence score is 6, matching the 6 beat baseline for this window. NGGT appears in 1 tracked Biotech story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NGGT. Shared-story counts are live from our verified record — not editorial picks.
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
Source: admin (in) · prnewswire.com
NGGT is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
